Navigation Links
BioMarin to Present at the Baird Growth Stock Conference
Date:5/7/2009

NOVATO, Calif., May 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Baird Growth Stock Conference in Chicago on Thursday, May 14, 2009 at 10:40 a.m. CT.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                      Media
    Eugenia Shen                   Susan Berg
    BioMarin Pharmaceutical Inc.   BioMarin Pharmaceutical Inc.
    (415) 506-6570                 (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin Announces First Quarter 2009 Financial Results
2. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
3. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
4. BioMarin to Present at the 4th Annual Citi Biotech Day
5. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
6. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
7. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
8. BioMarin to Present at the Piper Jaffray Healthcare Conference
9. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
10. BioMarin to Present at the Credit Suisse Healthcare Conference
11. BioMarin Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 MarketNewsUpdates.com News Commentary  ... The ... are being pressured as of late due to the rise ... management has a dramatic impact on patient,s quality of life ... activities for identifying new forms of opioid formulations that prevent ...
(Date:3/22/2017)... March 22, 2017   VWR ... of product and service solutions to laboratory ... has acquired EPL Archives, Inc., an international ... the entire regulated product research, development and ... storage and ancillary services. EPL Archives is ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper ... information on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent ... profiling of therapeutic antibodies. , To meet this demand, the team at ...
(Date:3/22/2017)... New York, NY (PRWEB) , ... March 21, 2017 , ... ... Medical Officer Summit (CMO Summit) to be held on May 10-11, 2017, at ... event in the country specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. ...
Breaking Biology Technology:
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis zum Jahr 2018 ... mehr als 50 Vertretern aus verschiedenen Branchen wurde aber klar, ... Prognose zu realisieren. ... Zu den Schwierigkeiten für Biobanking-Profis ... die Biobank, die Implementierung Zeit sparender Technologien, ein besseres ...
(Date:2/14/2017)... 14, 2017  Wake Forest Baptist Medical Center today ... chief executive officer (CEO). Freischlag joins the medical center ... McConnell , M.D., who last year announced that he ... Center, after leading it since 2008.   ... Wake Forest Baptist,s academic health system, which includes Wake ...
Breaking Biology News(10 mins):